Top

Published in:

01-10-2017 | Guideline Article

Diagnostics of the neuromyelitis optica spectrum disorders (NMOSD)

Authors: Diego Franciotta, Matteo Gastaldi, Arianna Sala, Francesca Andreetta, Elena Rinaldi, Maddalena Ruggieri, Rosaria Leante, Gianna Costa, Tiziana Biagioli, Luca Massacesi, Elena Bazzigaluppi, Raffaella Fazio, Sara Mariotto, Sergio Ferrari, Elisabetta Galloni, Francesco Perini, Elisabetta Zardini, Luigi Zuliani, Marco Zoccarato, Bruno Giometto, Antonio Bertolotto

Published in: Neurological Sciences | Special Issue 2/2017

Abstract

This document presents the guidelines for anti-aquaporin-4 (AQP4) antibody testing that has been developed following a consensus process built on questionnaire-based surveys, internet contacts, and discussions at workshops of the sponsoring Italian Association of Neuroimmunology (AINI) congresses. Essential clinical information on neuromyelitis optica spectrum disorders, indications and limits of anti-AQP4 antibody testing, instructions for result interpretation, and an agreed laboratory protocol (Appendix) are reported for the communicative community of neurologists and clinical pathologists.

Available only for authorised users

Wingerchuk DM, Banwell B, Bennett JL et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85:177–189CrossRefPubMedPubMedCentral

Jarius S, Wildemann B, Paul F (2014) Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol 176:149–164CrossRefPubMedPubMedCentral

Takeshita Y, Obermeier B, Cotleur AC et al (2016) Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro. Neurol Neuroimmunol Neuroinflamm 4:e311CrossRefPubMedPubMedCentral

Waters PJ, McKeon A, Leite MI (2012) Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology 78:665–661CrossRefPubMedPubMedCentral

Lennon VA, Wingerchuk DM, Kryzer TJ et al (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364:2106–2112CrossRefPubMed

Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202:473–477CrossRefPubMedPubMedCentral

Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG (2007) The spectrum of neuromyelitis optica. Lancet Neurol 6:805–815CrossRefPubMed

Sato DK, Callegaro D, Lana-Peixoto MA et al (2014) Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 82:474–481CrossRefPubMedPubMedCentral

Weinshenker BG, Wingerchuk DM (2014) The two faces of neuromyelitis optica. Neurology 82:466–467CrossRefPubMed

10.

Jarius S, Ruprecht K, Wildemann B et al (2012) Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation 9:14CrossRefPubMedPubMedCentral

11.

Kleiter I, Gahlen A, Borisow N et al (2016) Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol 79:206–216CrossRefPubMed

12.

Lechner C, Baumann M, Hennes EM et al (2016) Antibodies to MOG and AQP4 in children with neuromyelitis optica and limited forms of the disease. J Neurol Neurosurg Psychiatry 87:897–905CrossRefPubMed

13.

van Pelt ED, Wong YY, Ketelslegers IA, Hamann D, Hintzen RQ (2016) Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands. Eur J Neurol 23:580–587CrossRefPubMed

14.

Jarius S, Paul F, Franciotta D et al (2012) Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature. Mult Scler 18:1135–1143CrossRefPubMed

15.

Jarius S, Jacobi C, de Seze J et al (2011) Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders. Mult Scler 17:1067–1073CrossRefPubMed

16.

Pittock SJ, Lennon VA (2008) Aquaporin-4 autoantibodies in a paraneoplastic context. Arch Neurol 65:629–632PubMed

17.

Kitley J, Waters P, Woodhall M et al (2014) Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol 71:276–283CrossRefPubMed

18.

Majed M, Fryer JP, McKeon A, Lennon VA, Pittock SJ (2016) Clinical utility of testing AQP4-IgG in CSF: guidance for physicians. Neurol Neuroimmunol Neuroinflamm 3:e231CrossRefPubMedPubMedCentral

19.

Marignier R, Bernard-Valnet R, Giraudon P et al (2013) Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity. Neurology 80:2194–2200CrossRefPubMed

20.

Jarius S, Paul F, Franciotta D et al (2011) Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures. J Neurol Sci 306:82–90CrossRefPubMed

21.

Bennett JL, Lam C, Kalluri SR et al (2009) Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol 66:617–629CrossRefPubMedPubMedCentral

22.

Pisani F, Sparaneo A, Tortorella C et al (2013) Aquaporin-4 autoantibodies in neuromyelitis optica: AQP4 isoform-dependent sensitivity and specificity. PLoS One 8:e79185CrossRefPubMedPubMedCentral

23.

Jarius S, Wildemann B (2013) Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature. Brain Pathol 23:661–683CrossRefPubMed

24.

Nicchia GP, Mastrototaro M, Rossi A et al (2009) Aquaporin-4 orthogonal arrays of particles are the target for neuromyelitis optica autoantibodies. Glia 57:1363–1373CrossRefPubMed

25.

Rossi A, Pisani F, Nicchia GP et al (2010) Evidences for a leaky scanning mechanism for the synthesis of the shorter M23 protein isoform of aquaporin-4: implication in orthogonal array formation and neuromyelitis optica antibody interaction. J Biol Chem 285:4562–4569CrossRefPubMed

26.

Jarius S, Paul F, Fechner K et al (2014) Aquaporin-4 antibody testing: direct comparison of M1-AQP4-DNA-transfected cells with leaky scanning versus M23-AQP4-DNA-transfected cells as antigenic substrate. J Neuroinflammation 11:129CrossRefPubMedPubMedCentral

27.

Fryer JP, Lennon VA, Pittock SJ et al (2014) AQP4 autoantibody assay performance in clinical laboratory service. Neurol Neuroimmunol Neuroinflamm 1:e11CrossRefPubMedPubMedCentral

28.

Waters P, Reindl M, Saiz A et al (2016) Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. J Neurol Neurosurg Psychiatry 87:1005–1015CrossRefPubMedPubMedCentral

29.

Jarius S, Aboul-Enein F, Waters P et al (2008) Antibody to aquaporin-4 in the longterm course of neuromyelitis optica. Brain 131:3072–3080CrossRefPubMedPubMedCentral

30.

Valentino P, Marnetto F, Granieri L, Capobianco M, Bertolotto A (2017) Aquaporin-4 antibody titration in NMO patients treated with rituximab: a retrospective study. Neurol Neuroimmunol Neuroinflamm 4:e317CrossRefPubMed

31.

Karasawa R, Yudoh K, Ozaki S, Kato T (2011) Anti-endothelial cell antibodies (AECA) in patients with systemic vasculitis: our research using proteomics. Expert Opin Biol Ther 11:77–87CrossRefPubMed

Title: Diagnostics of the neuromyelitis optica spectrum disorders (NMOSD)
Authors: Diego Franciotta
Matteo Gastaldi
Arianna Sala
Francesca Andreetta
Elena Rinaldi
Maddalena Ruggieri
Rosaria Leante
Gianna Costa
Tiziana Biagioli
Luca Massacesi
Elena Bazzigaluppi
Raffaella Fazio
Sara Mariotto
Sergio Ferrari
Elisabetta Galloni
Francesco Perini
Elisabetta Zardini
Luigi Zuliani
Marco Zoccarato
Bruno Giometto
Antonio Bertolotto
Publication date: 01-10-2017
Publisher: Springer Milan
Published in: Neurological Sciences / Issue Special Issue 2/2017
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-017-3027-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Diagnostics of the neuromyelitis optica spectrum disorders (NMOSD)

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Special Issue 2/2017

Cerebrospinal fluid analysis and the determination of oligoclonal bands

Diagnostics of paraneoplastic neurological syndromes

Diagnostics of myasthenic syndromes: detection of anti-AChR and anti-MuSK antibodies

A bridge between evidence-based laboratory diagnostics and research in neuroimmunology: why standardizations and guidelines matter

Diagnostics of autoimmune encephalitis associated with antibodies against neuronal surface antigens

Diagnostics of dysimmune peripheral neuropathies